Trials / Unknown
UnknownNCT02605252
New Strategy Study of Functional Cure of Chronic Hepatitis B
A Study on Optimizing HBsAg Clearance in CHB Patients With Sequential Treatment of Pegylated Interferon Alpha-2b and Nucleoside Analogues
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated interferon alpha-2b and NAs.
Detailed description
CHB Patients who had received, and responded to, NAs for more than 12 months are switched to receive peginterferon alfa-2b 80 micrograms/week for 48 weeks and follow up for 48 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2b | peginterferon alfa-2b 80 micrograms/week for 48 weeks |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-09-01
- First posted
- 2015-11-16
- Last updated
- 2016-09-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02605252. Inclusion in this directory is not an endorsement.